Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bio-Rad Laboratories, Inc.NYSE: BIO

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $61.2M rose 1.2% year over year, ahead of the -14.3% change in trailing-twelve-month research & development. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Research & development amounted to 9.9% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.2% holds above the trailing-twelve-month pace of -14.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$61.2M-2.7% QoQ
Last fiscal yearDec 2025
$256.9M-13.2% YoY
LTMJun 2026
$261.1M-14.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.2%——
1 year-13.2%——
3-year CAGR+0.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
256.9M USD
Year-over-year change
-13.2%
4-year CAGR
-0.4%

Research & Development vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 research & development of $261.1M is the 4th highest of the 11 companies compared; the peer median is $92.36M.
  • Its year-over-year change of -14.3% is the 9th highest of 11, against a peer median of +1.8%.
  • Research & development amounts to 10.1% of revenue for BIO, versus a peer median of 7.6%.
BIO Competitors Peer median
Research & Development for BIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.67B +4.2%+1.5%6.5%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
BRKRBruker CorporationLTM Jun 2026$393.5M -1.6%+18.8%11.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M -27.1%-20.4%54.9%
RGENRepligen CorporationLTM Jun 2026$55.23M +14.4%+7.2%7.0%
AZTAAzenta, Inc.LTM Sep 2026$37.92M +31.1%+3.7%6.1%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M +13.2%+8.3%10.1%
Peer median (excluding BIO) $92.36M+1.8%+1.2%7.6%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.92B2.8B2.67B2.57B2.58B
Cost of Revenue1.28B1.23B1.24B1.19B1.24B
Gross Profit1.64B1.57B1.43B1.38B1.34B
Gross Margin56.1%55.9%53.4%53.7%52.0%
Research & Development260.64M256.89M247.43M295.9M256.9M
Selling, General & Admin877.12M827.83M841.7M814M819.9M
Operating Expenses1.14B1.08B1.09B1.11B1.08B
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
EBITDA5.59B(4.53B)(654.8M)(2.14B)1.21B
EBITDA Margin191.2%-161.6%-24.5%-83.5%46.8%
Operating Income500.34M482.62M337.8M269M270.5M
Operating Margin17.1%17.2%12.6%10.5%10.5%
Interest Income18.9M58M100.9M82M95.5M
Interest Expense1.55M38.11M49.44M48.9M49M
Other Income / Expenses4.95B(5.19B)(1.19B)(2.61B)725M
Income Before Tax5.45B(4.7B)(850.1M)(2.34B)995.5M
Pre-Tax Margin186.4%-167.9%-31.8%-91.3%38.5%
Income Tax Expense1.19B(1.08B)(212.78M)(498.3M)235.6M
Net Income4.25B(3.63B)(637.32M)(1.84B)759.9M
Net Margin145.6%-129.5%-23.9%-71.9%29.4%
EPS (Basic)142.61(121.79)(21.82)(65.36)27.87
EPS (Diluted)140.83(121.79)(21.82)(65.36)27.87
Weighted Avg Shares29.83M29.79M29.21M28.21M27.26M
Weighted Avg Shares (Diluted)30.21M29.79M29.21M28.21M27.28M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.